Virginia Meca-Lallana

Virginia Meca-Lallana

Auto-generated profile, based on publicly available information

Virginia Meca-Lallana

Servicio de Neurología, Hospital Universitario de la Princesa, 28006 Madrid, España

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
VMVirginia Meca-Lallana
Virginia Meca-Lallana
FGFrancisco Gascón-Giménez
Francisco Gascón-Giménez
RGRicardo C. Ginestal-López
Ricardo C. Ginestal-López
YHYolanda Higueras
Yolanda Higueras
NTNieves Téllez-Lara
Nieves Téllez-Lara
FPFrancisco Pérez-Miralles
Francisco Pérez-Miralles
Introduction: Cognitive impairment (CI) has a prevalence of 45–70% in people with multiple sclerosis (MS), producing a negative impact on their quality of life, personal life, and work. Early detection of CI has become an important aspect to be considered for an adequate follow-up, to optimize social adaptation and to implement specific cognitive rehabilitation strategies. The aim of this work is to propose a suitable cognitive evaluation of patients with MS based on available and efficient tools for diagnosis and monitoring purposes well supported by literature review and clinical experience.Methods: A multidisciplinary panel of professionals from the field of neurology, neuropsychology, and neuroimaging performed a literature review of the topic of cognitive impairment assessment. This was combined and completed with their clinical experience to produce a set of recommendations.Results: Some limitations to cognitive evaluation are described: shortage of time and resources during the neurology consultation, scarceness or absence of specialized professionals’ availability, importance of tests adaptation, and doubts about its use to define therapeutic efficiency. We recommend a baseline and annual screening evaluation, and we suggest a baseline and periodic neuropsychological assessment. The latter ought to change to a recommendation with the presence of either positive screening test, or subjective to cognitive complaints, screening-test results and patient or family report mismatch, or in specific social/work situations.Conclusions: Cognitive evaluation should be performed on all patients diagnosed with MS and throughout follow-up. It is necessary to support the creation of multidisciplinary MS teams to optimize the evaluation and follow-up of MS patients.

4 March 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
JFJosé I. Fernández-Velasco
José I. Fernández-Velasco
JKJens Kuhle
Jens Kuhle
EMEnric Monreal
Enric Monreal
VMVirginia Meca-Lallana
Virginia Meca-Lallana
JMJOSE EUSTASIO MECA-LALLANA
JOSE EUSTASIO MECA-LALLANA
LVLuisa M. Villar
Luisa M. Villar
Objective To analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS). Methods In this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determined effector, memory, and regulatory cells by flow cytometry at baseline and after 6 months of therapy. Wilcoxon matched paired tests were used to assess differences between baseline and 6 months9 results. p Values were corrected using the Bonferroni test. Results Ocrelizumab reduced the numbers of naive and memory B cells (p < 0.0001) and those of B cells producing interleukin (IL)-6, IL-10, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor-alpha (TNFα) (p < 0.0001 in all cases). By contrast, the proportions of plasmablasts and B cells producing GM-CSF and TNFα increased significantly, suggesting the need for treatment continuation. We also observed a decrease in CD20+ T-cell numbers (p < 0.0001) and percentages (p < 0.0001), and a clear remodeling of the T-cell compartment characterized by relative increases of the naive/effector ratios in CD4+ (p = 0.002) and CD8+ (p = 0.002) T cells and relative decreases of CD4+ (p = 0.03) and CD8+ (p = 0.004) T cells producing interferon-gamma. Total monocyte numbers increased (p = 0.002), but no changes were observed in those producing inflammatory cytokines. The immunologic variations were associated with a reduction of serum neurofilament light chain (sNfL) levels (p = 0.008). The reduction was observed in patients with Gd-enhanced lesions at baseline and in Gd− patients with baseline sNfL >10 pg/mL. Conclusions In PPMS, effector B-cell depletion changed T-cell response toward a low inflammatory profile, resulting in decreased sNfL levels.

1 September 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
VMVirginia Meca-Lallana
Virginia Meca-Lallana
CAClara Aguirre
Clara Aguirre
BRBeatrizdel Río
Beatrizdel Río
LCLaura Cardeñoso
Laura Cardeñoso
TATeresa Alarcon
Teresa Alarcon
JVJosé Vivancos
José Vivancos

1 September 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
CAClara Aguirre
Clara Aguirre
VMVirginia Meca-Lallana
Virginia Meca-Lallana
ABAna Barrios-Blandino
Ana Barrios-Blandino
BRBeatriz del Río
Beatriz del Río
JVJose Vivancos
Jose Vivancos

7 April 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
VMVirginia Meca-Lallana
Virginia Meca-Lallana
LBLeticia Berenguer-Ruiz
Leticia Berenguer-Ruiz
JCJoan Carreres-Polo
Joan Carreres-Polo
SESara Eichau-Madueño
Sara Eichau-Madueño
JFJaime Ferrer-Lozano
Jaime Ferrer-Lozano
FMFrancisco Carlos Pérez Miralles
Francisco Carlos Pérez Miralles
Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central nervous system, triggered by unknown environmental factors in patients with predisposing genetic risk profiles. The prevention of neurological disability is one of the essential goals to be achieved in a patient with MS. However, the pathogenic mechanisms driving the progressive phase of the disease remain unknown. It was described that the pathophysiological mechanisms associated with disease progression are present from disease onset. In daily practice, there is a lack of clinical, radiological, or biological markers that favor an early detection of the disease's progression. Different definitions of disability progression were used in clinical trials. According to the most descriptive, progression was defined as a minimum increase in the Expanded Disability Status Scale (EDSS) of 1.5, 1.0, or 0.5 from a baseline level of 0, 1.0–5.0, and 5.5, respectively. Nevertheless, the EDSS is not the most sensitive scale to assess progression, and there is no consensus regarding any specific diagnostic criteria for disability progression. This review document discusses the current pathophysiological concepts associated with MS progression, the different measurement strategies, the biomarkers associated with disability progression, and the available pharmacologic therapeutic approaches.

18 July 2021 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
IMIrene Moreno-Torres
Irene Moreno-Torres
VLVirginia Meca Lallana
Virginia Meca Lallana
LCLucienne Costa-Frossard
Lucienne Costa-Frossard
COCelia Oreja-Guevara
Celia Oreja-Guevara
CAClara Aguirre
Clara Aguirre
JDJose Manuel Garcia Dominguez
Jose Manuel Garcia Dominguez
Background and purpose: Limited information is available on incidence and outcomes of COVID‐19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS‐CoV‐2 infection and COVID‐19‐related outcomes in patients with MS, and compared these with the general population.Methods: A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit admission, and death in patients with MS and COVID‐19. National government outcomes and seroprevalence data were used for comparison. The study was conducted at 14 specialist MS treatment centers in Madrid, Spain, between February and May 2020.Results: Two‐hundred nineteen patients were included in the registry, 51 of whom were hospitalized with COVID‐19. The mean age ± standard deviation was 45.3 ± 12.4 years, and the mean duration of MS was 11.9 ± 8.9 years. The infection incidence rate was lower in patients with MS than the general population (adjusted incidence rate ratio = 0.78, 95% confidence interval [CI] = 0.70–0.80), but hospitalization rates were higher (relative risk = 5.03, 95% CI = 3.76–6.62). Disease severity was generally low, with only one admission to an intensive care unit and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease‐modifying treatment and hospitalization risk.Conclusions: Patients with MS do not appear to have greater risks of SARS‐CoV‐2 infection or severe COVID‐19 outcomes compared with the general population. The decision to start or continue disease‐modifying treatment should be based on a careful risk–benefit assessment.